Mylan profit rises on higher generic drug sales in North America Thu Oct 25, 2012 7:33am EDT (Reuters) - Mylan Inc's quarterly profit rose 35 percent, driven by a rise in sales of EpiPen, its anti-allergen delivery product, and its generic drugs in North America, and the drugmaker raised its adjusted earnings forecast for 2012. The company raised its full-year 2012 adjusted earnings forecast to between $2.50 and $2.60 per share from its previous forecast of between $2.45 and $2.55 per share. Third-quarter net income rose to $211.3 million or 51 cents per share, from $156.7 million, or 36 cents per share, a year earlier. Total revenue rose nearly 14 percent to $1.79 billion. Mylan, which is one of the world's largest generic drugmakers, has more than 1,100 products. The company's generics business relies heavily on the U.S. patent cliff - a raft of patent expiries which will stretch till 2016.